*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Semaglutide forms head-to-head
Form
Manufacturer
FDA Indication
Cash price
Ozempic
Novo Nordisk
Type 2 diabetes
~$935-$1,000/mo
Wegovy
Novo Nordisk
Chronic weight management; CV risk reduction
~$1,349/mo
Rybelsus
Novo Nordisk
Type 2 diabetes (oral)
~$935/mo
Compounded semaglutide
503A or 503B pharmacy
Not FDA-approved
$145-$297/mo
Pivotal trial results
STEP-1 (NEJM 2021, PMID 33567185) — semaglutide 2.4 mg: 14.9% weight loss / 68 weeks vs 2.4% placebo
SUSTAIN-6 (NEJM 2016, PMID 27633186) — semaglutide CV safety in T2D + high CV risk
SELECT (NEJM 2023, PMID 37952131) — 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD
FLOW (NEJM 2024, PMID 38785189) — 24% reduction in major kidney/CV events in T2D + CKD
SURPASS-2 (NEJM 2021, PMID 34170647) — tirzepatide ~47% greater weight loss vs semaglutide 1 mg
